Who are allovectin-7/dacarbazine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etakridin, HU-014, telomerase peptide vaccine GV1001.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allovectin-7-dacarbazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

allovectin-7/dacarbazine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

allovectin-7/dacarbazine (allovectin-7/dacarbazine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DNA vaccine, chemotherapy. Area: Oncology.

phase 3 DNA vaccine, chemotherapy Telomerase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

allovectin-7/dacarbazine (allovectin-7/dacarbazine) — Vical. Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
allovectin-7/dacarbazine TARGET	allovectin-7/dacarbazine	Vical	phase 3	DNA vaccine, chemotherapy	Telomerase
Etakridin	ETHACRIDINE		marketed	ethacridine	Telomerase reverse transcriptase, Reverse transcriptase, Reverse transcriptase/RNaseH
HU-014	HU-014	Huons Co., Ltd.	phase 3	Telomerase inhibitor	Telomerase
telomerase peptide vaccine GV1001	telomerase peptide vaccine GV1001	Royal Liverpool University Hospital	phase 3		Telomerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DNA vaccine, chemotherapy class)

Vical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). allovectin-7/dacarbazine — Competitive Intelligence Brief. https://druglandscape.com/ci/allovectin-7-dacarbazine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab